Profile

One more thing to add, Kevin you brought up a good point, but the IRRs incidence was 13% and our group felt it wasn't very impressive. Our other experience with SQ data, like daratumumab, shows something similar. -- Eve Segal, PharmD, BCOP Pronouns:She/Her/Hers Clinical Pharmacy Operations ...

Eek, maybe we are cowboys over here, but we did not build in a observation time. There isn't an observation time in the PI, but please correct me if I am wrong! Gives me flashbacks to when subq dara went live and we had a very long post-dose observation time. -- Eve Segal, PharmD, BCOP Pro ...

We have a project to help facilitate outpatient administration of tarlatamab that mimics some of the workflows Lia described in UVA. Patients receive tarlatamab and then after infusion are eligible to go home. A clinic nurse will perform a phone assessment to screen for CRS/ICANS after infusion. Patients ...